<DOC>
	<DOC>NCT01427868</DOC>
	<brief_summary>The study is to compare pharmacokinetics of LB80331 and LB80317, which are the metabolites of LB80380, after a single oral administration of LB80380 free base 150 mg (60 mg + 90 mg) tablet or LB80380 maleate tablet 183 mg (150 mg as a free base) in healthy male subjects.</brief_summary>
	<brief_title>Bioequivalence of LB80380 Free Base and Maleate Salt Tablets</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male with good health 20 to 45 years of age at screening Body weight Â±20% of ideal body weight Willingness and ability to comply with study procedures and communicate with investigators Provided written consent voluntarily after informed of all the pertinent aspects of the trial Clinically significant abnormality on medical interview, physical examination, electrocardiogram or clinical laboratory evaluations Clinically significant acute or chronic medical conditions Use of prescriptive medicine within 14 days, or overthecounter drug within 7 days before the first day of drug administration Participation in clinical trial within 3 months before the first day of drug administration Alcohol abuse Habitual smoker Habitual user of herbal medicine Use of grapefruitcontaining food or grapefruit juice during the study period Positive drug abuse test and Positive HBsantigen, HCVantibody, or HIVantibody test</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>LB80380</keyword>
	<keyword>bioequivalence</keyword>
</DOC>